|
Odds ratios, from multivariable logistic regression models, for outcomes within 3 years |
|||
| Category |
n (%) |
Acute organ failure within 3 years; odds ratio (95% CI)b |
Death within 3 years; odds ratio (95% CI) |
|
|
|||
| Age group |
|||
| 44–49 |
4,106 (26.7) |
1.0 |
1.0 |
| 50–54 |
4,007 (26.0) |
1.2 (0.6–2.4) |
0.9 (0.6–1.4) |
| 55–59 |
3,761 (24.4) |
1.6 (0.9–3.0) |
1.8 (1.2–2.6) |
| 60–66 |
3,534 (22.9) |
2.9 (1.6–5.2) |
3.0 (2.1–4.3) |
| Sex |
|||
| Male |
6,918 (44.9) |
1.0 |
1.0 |
| Female |
8,490 (55.1) |
0.6 (0.4–0.9) |
0.6 (0.4–0.7) |
| Race |
|||
| White |
11,365 (73.8) |
1.0 |
1.0 |
| Black |
4,043 (26.2) |
0.7 (0.5–1.1) |
2.0 (1.5–2.6) |
| Smoking status |
|||
| Current smoker |
4,394 (28.5) |
1.2 (0.7–1.9) |
1.8 (1.4–2.5) |
| Former smoker |
4,964 (32.2) |
1.0 (0.6–1.6) |
1.1 (0.8–1.5) |
| Never smoker |
6,050 (39.3) |
1.0 |
1.0 |
| Diabetes mellitus |
|||
| Yes |
1,830 (11.9) |
3.2 (2.1–4.7) |
2.7 (2.1–3.5) |
| No |
13,578 (88.1) |
1.0 |
1.0 |
| Body mass index |
|||
| <20 |
506 (3.3) |
1.3 (0.6–2.8) |
1.1 (0.7–2.0) |
| 20–24 |
4,610 (29.9) |
1.0 |
1.0 |
| 25–29 |
6,058 (39.3) |
0.8 (0.5–1.2) |
0.8 (0.6–1.1) |
| ≥30 |
4,234 (27.5) |
0.9 (0.6–1.4) |
0.8 (0.6–1.1) |
| Education level |
|||
| <12 years |
3,646 (23.7) |
1.3 (0.8–1.9) |
1.5 (1.1–2.0) |
| 12 years |
4,991 (32.4) |
0.8 (0.5–1.3) |
1.4 (1.1–1.9) |
| ≥12 years |
6,771 (43.9) |
1.0 |
1.0 |
| GOLD categorya |
|||
| GOLD 3 or 4 |
280 (1.8) |
9.4 (4.8–18.4) |
4.3 (2.6–7.0) |
| GOLD 2 |
1,469 (9.5) |
3.6 (2.0–6.4) |
2.2 (1.5–3.2) |
| GOLD 1 |
1,677 (10.9) |
1.9 (0.98–3.6) |
1.3 (0.9–1.9) |
| GOLD 0 |
2,170 (14.1) |
2.8 (1.6–5.2) |
2.4 (1.7–3.5) |
| Restricted |
1,295 (8.4) |
2.9 (1.7–5.0) |
1.6 (1.1–2.3) |
| Normal |
8,517 (55.3) |
1.0 |
1.0 |
|
Data are taken from the Atherosclerosis Risk in Communities study 1986–1989 and follow-up. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. aModified Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3 or 4 (FEV1/FVC < 0.70 and FEV1 < 50% predicted), GOLD stage 2 (FEV1/FVC < 0.70 and FEV1 ≥ 50 to < 80% predicted), GOLD stage 1 (FEV1/FVC < 0.70 and FEV1 ≥ 80%), restricted (FEV1/FVC ≥ 0.70 and FVC < 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung function abnormality). All lung function measurements were pre-bronchodilator values. b95% confidence intervals (CI) that do not include 1.0 are significant at the p = 0.05 level. | |||
Slynkova et al. Critical Care 2006 10:R137 doi:10.1186/cc5051 |
|||